This accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9).
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.
These activities have been supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
Hot Topics in Dyslipidemia
Individualizing LDL-C Targets in High-Risk Patients
Novel Nonstatin LDL-C Targets in High-Risk Patients
Long-term Cardiovascular Outcomes Trials With PCKS9 Inhibitors
Collaborating with Patients to Reduce Long-Term Hypercholesterolemia Risks
Tailored Lipid-Lowering Regiments for Specific Very High-Risk Profiles
